Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab plus best supportive care versus placebo plus best supportive care in previously treated advanced gastric or gastroesophageal junction adenocarcinoma
RBR-5f6qjgPhase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Ramucirumab + best supportive care with Placebo + best supportive care (2 arms). Primary endpoint: Overall survival. Started Feb 2011; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on RBR-5f6qjg.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-5f6qjg.